Patent · US Expired

Method for identifying a compound to be tested for an ability to reduce immune rejection by determining Stat4 and Stat6 proteins

US6534277B1 · kind B1 · utility

18Cited by
23References
9Claims
0Family size

Assignee

Inventors

Key dates

Filing dateOct 5, 2001
Grant dateMar 18, 2003
Priority date
Expiry dateOct 29, 2021

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12Q2600/158
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention relates to methods for identifying compounds that can reduce immune rejection, for example, transplant- or autoimmune disorder-related immune rejection. The present invention is based, in part, on the discovery, demonstrated herein, that immune rejection can be monitored by determining the amount of particular members of the Jak/Stat signal transduction pathway present within an affected tissue. The present invention is further based, in part, on the discovery, demonstrated herein, that immune rejection can be reduced and tolerance can be induced by modulating the amount of these particular members of the Jak/Stat signal transduction pathway present, expressed or active within an affected tissue. In particular, the results demonstrate that immune rejection can be monitored by determining the amount of mRNA or protein of Stat1, Stat3, Stat4, Stat6, SOCS1, or SOCS3 present, e.g., in an affected tissue.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.